| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | EPCAM |
| Uniprot No | P16422 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 24-265aa |
| 氨基酸序列 | QEECVCENYKLAVNCFVNNNRQCQCTSVGAQNTVICSKLAAKCLVMKAEM NGSKLGRRAKPEGALQNNDGLYDPDCDESGLFKAKQCNGTSTCWCVNTAG VRRTDKDTEITCSERVRTYWIIIELKHKAREKPYDSKSLRTALQKEITTR YQLDPKFITSILYENNVITIDLVQNSSQKTQNDVDIADVAYYFEKDVKGE SLFHSKKMDLTVNGEQLDLDPGQTLIYYVDEKAPEFSMQGLKVDHHHHHH |
| 预测分子量 | 28 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇与EPCAM重组蛋白相关的代表性文献(注：内容为模拟概括，实际文献需通过数据库查询)：
1. **文献名称**: "Structural and functional characterization of recombinant human EpCAM protein"
**作者**: Smith A, et al.
**摘要**: 研究通过哺乳动物表达系统成功表达并纯化重组人EPCAM蛋白，分析其结构稳定性及与抗体CD326的结合特性，证实其在体外诊断试剂开发中的潜力。
2. **文献名称**: "EpCAM-based recombinant protein enhances CAR-T cell targeting in solid tumors"
**作者**: Zhang L, et al.
**摘要**: 构建含重组EpCAM蛋白的嵌合抗原受体(CAR)，验证其与肿瘤细胞表面EpCAM的高亲和力，为结直肠癌等实体瘤的免疫治疗提供新策略。
3. **文献名称**: "Recombinant EpCAM extracellular domain as a serum biomarker for epithelial cancers"
**作者**: Gupta R, et al.
**摘要**: 开发重组EpCAM胞外域蛋白作为ELISA检测工具，证实其在乳腺癌和卵巢癌患者血清中的异常高表达，提示其作为癌症早期诊断标志物的可能性。
(提示：实际引用请通过PubMed/Google Scholar检索关键词"recombinant EpCAM protein"获取最新文献)
Epithelial cell adhesion molecule (EPCAM), also known as CD326. is a transmembrane glycoprotein predominantly expressed on epithelial cells and solid tumors. It plays a critical role in cell-cell adhesion, intracellular signaling, and cell proliferation. Dysregulation of EPCAM is linked to cancer progression, metastasis, and poor prognosis, making it a biomarker for carcinomas and a target for therapeutic interventions.
Recombinant EPCAM proteins are engineered versions produced via heterologous expression systems, such as mammalian cells (e.g., HEK293 or CHO) or *E. coli*. Mammalian systems are preferred for generating glycosylated, post-translationally modified proteins that mimic native EPCAM, while bacterial systems offer cost-effective production of non-glycosylated variants. These recombinant proteins typically include functional domains like the extracellular region (two EGF-like domains and a cysteine-rich region) critical for homophilic interactions and antibody binding.
In research, recombinant EPCAM serves as an antigen for antibody development, a standard in immunoassays (ELISA, flow cytometry), or a tool to study tumor biology. Its applications extend to diagnostic kits for detecting circulating tumor cells (CTCs) and therapeutic strategies, including EPCAM-targeted CAR-T cells, monoclonal antibodies (e.g., catumaxomab), and cancer vaccines. However, challenges persist in maintaining protein stability, solubility, and native conformation during production. Advances in protein engineering, such as codon optimization or fusion tags, aim to enhance yield and functionality. Ongoing studies explore its role in stem cell regulation and epithelial-mesenchymal transition (EMT), further broadening its biomedical relevance.
×
